UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000026387
Receipt No. R000030302
Scientific Title A verification study on improvements in the immune system and defecation: A randomized open trial
Date of disclosure of the study information 2017/03/03
Last modified on 2017/11/20

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A verification study on improvements in the immune system and defecation: A randomized open trial
Acronym A verification study on improvements in the immune system and defecation
Scientific Title A verification study on improvements in the immune system and defecation: A randomized open trial
Scientific Title:Acronym A verification study on improvements in the immune system and defecation
Region
Japan

Condition
Condition Japanese adults who are healthy or regularly see a doctor
Classification by specialty
Medicine in general Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To verify the effects of the test food on immune system and defecation
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2 Pragmatic
Developmental phase Not applicable

Assessment
Primary outcomes 1. Scoring of immunological vigor
*Assess at 0 and 4 weeks after consuming
Key secondary outcomes 1. Immunity test
T lymphocyte age, Immunological age, T cells, CD4+T cells / CD8+T cells ratio, naive T cells, naive T cells / memory T cells ratio, B cells, NK cells, CD8+CD28+T cells, T-cell proliferation index, CD4+T cells, CD8+T cells, memory T cells
*Assess at 0 and 4 weeks after consuming

2. Subjective symptoms
a. The Japanese version of Constipation Assessment Scale MT version (CAS-MT)
b. Bristol Stool Scale
c. Bowel movement diary
d. The Likert scale method
*Above a, b, and d, assess at 0 and 4 weeks after consuming
*Above c, record when defecating

3. Saliva test
Salivary immunoglobulin A (sIgA)
*Assess at 0 and 4 weeks after consuming

4. Blood test
High-sensitive CRP, albumin, prealbumin
*Assess at 0 and 4 weeks after consuming

5. Physical examination
Muscle mass, grip strength
*Assess at 0 and 4 weeks after consuming

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Open -no one is blinded
Control Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Food
Interventions/Control_1 Duration: 4 weeks
Test Material: Nutrient-rich liquid food
Dosage: Drink 1 pack (125 mL) for a day before breakfast
Interventions/Control_2 Duration: 4 weeks
Test Material: Orange juice
Dosage: Drink 1 pack (125 mL) for a day after breakfast
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
65 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1. Japanese adults, who is 65 years and more, are aware of daily fatigue

2. Priority selection is made in the order of II: warning zone, III: observation zone, and IV: safety zone, in immunological grade at baseline
*However, V (sufficiently high) and I (critical zone) are excluded
Key exclusion criteria 1. Those who have the medical history or under the treatment of malignant tumor

2. Those who have the medical history or under the treatment of autoimmune disease

3. Those who have the medical history or under the treatment of inflammatory bowel disease

4. Those who are currently hospitalized

5. Those who use or take "Foods for Specified Health Uses" and "Foods with Functional Claims" in daily

6. Those who eat Natto, yogurt, and food and beverage including lactic acid bacteria in daily

7. Those who are smokers

8. Those who take anti-allergic drugs

9. Currently taking supplements

10. Those who are allergic to medicines and/or the test food related products

11. Those who are pregnant, breast-feeding, and plan to become a pregnant

12. Those who had participated another clinical test for three months when you signed the informed consent form for this trial

13. Others considered as inappropriate for the study by the physician
Target sample size 60

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Kazuo YAMAMOTO
Organization ORTHOMEDICO Inc.
Division name R&D Department
Zip code
Address 2F Sumitomo Fudosan Korakuen Bldg., 1-4-1 Koishikawa, Bunkyo-ku, Tokyo.
TEL 03-3818-0610
Email kazu@orthomedico.jp

Public contact
Name of contact person
1st name
Middle name
Last name Naoko SUZUKI
Organization ORTHOMEDICO Inc.
Division name R&D Department
Zip code
Address 2F Sumitomo Fudosan Korakuen Bldg., 1-4-1 Koishikawa, Bunkyo-ku, Tokyo.
TEL 03-3818-0610
Homepage URL
Email nao@orthomedico.jp

Sponsor
Institute ORTHOMEDICO Inc.
Institute
Department

Funding Source
Organization CLINICO CO.,LTD
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor Seishin-kai Medical Association Inc, Takara Medical Clinic.
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 医療法人社団 盛心会 タカラクリニック (東京都)
Seishin-kai Medical Association Inc, Takara Medical Clinic (Tokyo)

Other administrative information
Date of disclosure of the study information
2017 Year 03 Month 03 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2017 Year 02 Month 28 Day
Date of IRB
Anticipated trial start date
2017 Year 03 Month 04 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2017 Year 03 Month 03 Day
Last modified on
2017 Year 11 Month 20 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030302

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.